Direkt zum Inhalt
Merck

The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.

Annals of neurology (1996-01-01)
O A Petroff, D L Rothman, K L Behar, D Lamoureux, R H Mattson
ZUSAMMENFASSUNG

Gabapentin has come into clinical use as adjunctive therapy in the treatment of epilepsy. Designed to mimic gamma-aminobutyric acid (GABA), its mechanism of action remains elusive. In vivo measurements of GABA in human brain were made using 1H magnetic resonance spectroscopy. We used a 2.1-T magnetic resonance imager-spectrometer and an 8-cm surface coil to measure a 13.5-cm3 volume in the occipital cortex. GABA levels were measured in 14 patients enrolled in an open-lbel trial of gabapentin. GABA was elevated in patients taking gabapentin compared with 14 complex partial epilepsy patients, matched for antiepileptic drug treatment. Brain GABA levels appeared to be higher in patients taking high-dose gabapentin (3,300-3,600 mg/day) than in those taking standard doses (1,200-2,400 mg/day). Gabapentin appears to increase human brain GABA levels.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Supelco
Gabapentin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Gabapentin, solid
Supelco
Gabapentin, Pharmaceutical Secondary Standard; Certified Reference Material